S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
NASDAQ:BIS

ProShares UltraShort Nasdaq Biotechnology - BIS Stock Forecast, Price & News

$17.99
-0.46 (-2.49%)
(As of 12/2/2022 08:59 PM ET)
Add
Today's Range
$17.92
▼
$18.82
50-Day Range
$17.99
▼
$27.30
52-Week Range
$17.92
▼
$35.64
Volume
13,300 shs
Average Volume
24,269 shs
Market Capitalization
$5.40 million
P/E Ratio
N/A
Dividend Yield
0.00%
Price Target
N/A
Receive BIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProShares UltraShort Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Receive BIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProShares UltraShort Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer ProShares
Fund NameProShares UltraShort Nasdaq Biotechnology
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:BIS
Inception Date4/6/2010
Fund ManagerMichael Neches, Tarak Dave

Fund Focus

Asset ClassEquity
BenchmarkNasdaq Biotech Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$19.04 million
Average Daily Volume$100,288.40
Discount/Premium0.02%

ETF Expenses

Management Fee0.75%
Other Expenses0.36%
Total Expenses1.11%
Fee Waiver-0.16%
Net Expenses0.95%

Administrator, Advisor and Custodian

AdministratorJ.P. Morgan Investor Services Co.
AdvisorProShare Advisors LLC
CustodianJPMorgan Chase Bank, N.A.
DistributorSEI Investments Distribution Co.
Transfer AgentJPMorgan Chase Bank, N.A.
Trustee
Lead Market MakerVirtu Financial

Geographic Exposure of BIS

Currency Exposure of BIS














BIS Stock - Frequently Asked Questions

How have BIS shares performed in 2022?

ProShares UltraShort Nasdaq Biotechnology's stock was trading at $20.0691 on January 1st, 2022. Since then, BIS stock has decreased by 10.4% and is now trading at $17.99.
View the best growth stocks for 2022 here
.

Are investors shorting ProShares UltraShort Nasdaq Biotechnology?

ProShares UltraShort Nasdaq Biotechnology saw a decrease in short interest in November. As of November 15th, there was short interest totaling 32,500 shares, a decrease of 35.6% from the October 31st total of 50,500 shares. Based on an average trading volume of 15,800 shares, the days-to-cover ratio is currently 2.1 days.
View ProShares UltraShort Nasdaq Biotechnology's Short Interest
.

When did ProShares UltraShort Nasdaq Biotechnology's stock split?

ProShares UltraShort Nasdaq Biotechnology's stock reverse split on the morning of Tuesday, August 18th 2020. The 1-4 reverse split was announced on Tuesday, August 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 17th 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of ProShares UltraShort Nasdaq Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProShares UltraShort Nasdaq Biotechnology investors own include Sanofi (SNY), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Intel (INTC), Quest Diagnostics (DGX), Micron Technology (MU), Pfizer (PFE), Cidara Therapeutics (CDTX) and Vertex Pharmaceuticals (VRTX).

What is ProShares UltraShort Nasdaq Biotechnology's stock symbol?

ProShares UltraShort Nasdaq Biotechnology trades on the NASDAQ under the ticker symbol "BIS."

Who are ProShares UltraShort Nasdaq Biotechnology's major shareholders?

ProShares UltraShort Nasdaq Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include Citadel Advisors LLC (8.60%), IMC Chicago LLC (7.78%) and Tower Research Capital LLC TRC (2.71%).
View institutional ownership trends
.

How do I buy shares of ProShares UltraShort Nasdaq Biotechnology?

Shares of BIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProShares UltraShort Nasdaq Biotechnology's stock price today?

One share of BIS stock can currently be purchased for approximately $17.99.

How much money does ProShares UltraShort Nasdaq Biotechnology make?

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) has a market capitalization of $5.40 million.

How can I contact ProShares UltraShort Nasdaq Biotechnology?

ProShares UltraShort Nasdaq Biotechnology's mailing address is SUITE 1000, 7501 WISCONSIN AVENUE, Bethesda, MD 20814, United States. The official website for the company is www.proshares.com. The company can be reached via phone at +1-240-4976400.

This page (NASDAQ:BIS) was last updated on 12/5/2022 by MarketBeat.com Staff